Chiral Catalysis Technology

●  We developed scale-up synthesis processes for over 100 chiral ligands and catalysts, more than 40 of which are marketed worldwide.

●  We applied asymmetric hydrogenation to the production of multiple chiral drugs, inventing novel synthesis processes for key chiral intermediates of various products, including N0701, ensartinib, crizotinib, ezetimibe, rivastigmine, montelukast, sitagliptin, and dapoxetine. By significantly reducing production costs, energy consumption, and waste, we improve cost effectiveness and process stability, making our pharmaceutical process more environmentally friendly, safer, and more reliable.

●  We applied favorable catalysts to drug products in multiple preclinical studies and early-phase clinical trials, and developed novel synthesis processes, facilitating the translation of scientific discoveries into industrial applications. We also used chiral phase-transfer catalysts in asymmetric cycloaddition to synthesize valuable chiral intermediates for drugs；

●  As of the end of 2022, we published eight articles on the asymmetric catalysis platform in international journals, including ACS Catalysis, Organic Letters, Chemical Communications, and OPRD, filed 22 patent applications, and obtained 12 granted patents. These robust intellectual property assets have enhanced our international profile.

Equipment

●  Agilent Gas Chromatography (GC) System
●  Agilent High Performance Liquid Chromatography (HPLC) System
●  Glove boxes
●  High-pressure reactors of multiple scales
●  Parallel reaction stations
●  Continuous hydrogenation reactors
 

Advantages

●  In-house design and synthesis of chiral phosphine ligands, chiral small molecule catalysts, and chiral metal complexes (catalysts).

●  Strong capabilities in asymmetric hydrogenation, asymmetric Suzuki coupling, and asymmetric cycloaddition, providing efficient tools for the synthesis and development of chiral drugs and intermediates.

●  Research on mechanisms of general asymmetric reactions, providing technical guidance for the development of efficient asymmetric catalysis and ligands.